Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 10,824 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: Porphyrias
Interventions: Web-based Survey; Other
Lead sponsor: University of South Florida; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Rett Syndrome
Interventions: Trofinetide; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 5 Years to 21 Years · Female only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more

Conditions: Persistent Tic Disorders, Tourette Disorder
Interventions: Comprehensive Behavioral Intervention for Tics - Enhanced (CBIT-E); Behavioral
Lead sponsor: Marquette University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hurler's Syndrome, Maroteaux-Lamy Syndrome, Sly Syndrome, Alpha Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Sphingolipidoses, Krabbe Disease, Wolman's Disease, Niemann-Pick Disease Type B, Niemann-Pick Disease, Type C
Interventions: Stem Cell Transplantation, Cyclophosphamide, Campath-1H, Busulfan; Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hydration Status
Interventions: Hydration education and self-assessment; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Congenital Heart Disease, Prematurity, Necrotizing Enterocolitis
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Up to 1 Month
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Thoracic Insufficiency Syndrome
Interventions: Xenon-129; Device
Lead sponsor: Patrick Cahill, MD; Other
Eligibility: 6 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor
Interventions: Computed Tomography, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Quality-of-Life Assessment, Single Photon Emission Computed Tomography, Magnetic Resonance Imaging, Ultrasound Imaging, Biospecimen Collection, Biopsy, Questionnaire Administration; Procedure · Other · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Interventions: Teprotumumab, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more

Conditions: Pectus Excavatum
Interventions: Patient controlled analgesia, Continuous thoracic epidural infusions, Continuous paravertebral blockade; Device · Procedure
Lead sponsor: Ralph Beltran; Other
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Ebstein Anomaly
Interventions: Autologous Bone Marrow-derived Mononuclear Cells, Insertable cardiac monitor; Biological · Device
Lead sponsor: Timothy J. Nelson; Other
Eligibility: 6 Months to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions: Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care; Combination Product · Other
Lead sponsor: Kari Nadeau, MD, PhD; Other
Eligibility: 1 Week to 12 Weeks
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 4
States / cities: Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more

Conditions: Atopic Dermatitis
Interventions: Skin Cleanser Combination No.1; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2031 – 2039
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Patent Ductus Arteriosus
Interventions: INVOS Cerebral/Somatic oximeter; Device
Lead sponsor: University of Louisville; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Lousiville, Kentucky

Conditions: Friedreich Ataxia, Healthy Volunteers
Interventions: Buccal Swabs, Blood Draws and Skin Punch Biopsy; Diagnostic Test
Lead sponsor: Larimar Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Gout
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Progeria
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 6 Months to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease, Sickle Cell Anemia
Interventions: Voxelotor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Farmington, Connecticut • Atlanta, Georgia • Detroit, Michigan + 7 more

Conditions: Hip; Anomaly
Interventions: Mobilization with movement and stretching, stretching or control; Procedure
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
Interventions: pTVG-HP, pTVG-AR, Pembrolizumab; Biological · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: St Louis, Missouri • Madison, Wisconsin

Conditions: Cholestasis, Liver Diseases
Interventions: Omegaven; Drug
Lead sponsor: Catherine Cibulskis, MD; Other
Eligibility: Up to 1 Year
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Phenylketonuria
Interventions: Kuvan, Diet; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 4 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Atopic Dermatitis (AD)
Interventions: OTC Drug for Atopic Dermatitis in Cream form; Drug
Lead sponsor: Good Molecules, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis
Interventions: SB656933, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 14 more

Search by objective public record fields.

Evidence-based Assessment of Medication Sensitivity in Acute Hepatic Porphyria

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

Online-Delivered Comprehensive Behavioral Intervention for Tics-Enhanced (CBIT-E)

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

The Impact of Self-assessment on Hydration

Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease

Pulmonary Assessment in Thoracic Insufficiency Syndrome Patients

Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

Nuss Procedure: Clinical Options in Pediatric Pain Management?

Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly

Seal, Stopping Eczema and Allergy Study

Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

Brain, Gut and Kidney Blood Flow During Medical Closure of PDA

Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers

Impact of Unapproved Drug Initiative on Colchicine Use

Clinical Studies of Progeria

Actigraphy Improvement With Voxelotor (ActIVe) Study

Examining the Effects of a Mobilization With Movement and a Dynamic Stretch With Over Pressure on Hip Flexion.

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

28 Day Repeat Dose in Cystic Fibrosis Patients